Phaseline

Companies › Corbus Pharmaceuticals

Corbus Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CRB-701–Phase 3Oropharyngeal Carcinoma (OPC); Solid Tumor, AdultJan 2027
CRB-601
αvβ8 integrin antagonist monoclonal antibody
ITGAV, ITGB8Phase 1Solid TumorDec 2026
CRB-913–Phase 1Obese But Otherwise Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07310901CRB-913Phase 1Obese But Otherwise Healthy ParticipantsMetabolic and endocrineAug 2026
NCT06603844CRB-601Phase 1Solid TumorOncologyDec 2026
NCT06265727CRB-701Phase 1Solid Tumor, AdultOncologyJan 2027
NCT07768189CRB-701Phase 3Oropharyngeal Carcinoma (OPC)OncologyDec 2027

From the company's SEC filings

Cash and short-term investments of $118m on 2026-06-30; operating cash outflow about $112m a year; runway about 13 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ITGAV (1) ITGB8 (1)

Companies with the same targets

–

Companies built like this

Kura Oncology Eikon Therapeutics ALX Oncology Arcus Biosciences Lyell Immunopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.